From Hepatic Enzyme Alterations to Drug Metabolic Dysfunction: A Systematic Review of Prolonged Pharmacotherapy
Journal of Diabetes, Metabolism and Endocrinology · 2026
DOI: 10.61336/jdme.0704.10 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Diabetes, Metabolism and Endocrinology, 2026. Verfasst von Sarthak Satapathy und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Prolonged exposure to medicines may produce laboratory abnormalities, clinically significant hepatic injury, or changes in hepatic drug-metabolizing enzyme activity. These phenomena overlap but are not interchangeable.
Objective
To critically synthesize human evidence connecting repeated or extended pharmacotherapy with hepatic enzyme alterations, liver injury and altered drug disposition.
Methods
A structured search of PubMed/MEDLINE-indexed records, accessible full-text articles and publisher databases identified clinical trials, longitudinal cohorts, comparative studies, pharmacokinetic experiments and a chronic-exposure histopathological case series. The PRISMA selection accounting presents 811 records identified, 164 duplicates removed, 647 records screened, 120 full-text reports assessed and 14 primary reports included in the domain-based narrative synthesis. Findings were organized into biochemical injury, clinically significant hepatotoxicity, enzyme induction, enzyme inhibition and cumulative structural damage; reported effect estimates and denominators were preserved.
Results
In a randomized trial of 4,786 adults, liver-test elevations occurred in 43.6% with low-dose methotrexate versus 24.1% with placebo (hazard ratio 2.14, 95% confidence interval 1.93-2.37). In a 213-person methotrexate cohort, 21% developed alanine aminotransferase >1.5 times the upper limit of normal over a mean 4.3 years. A study of 1,928 tuberculosis-treatment recipients recorded drug-induced liver injury in 3.0%, whereas a randomized latent-tuberculosis trial found grade 3-4 hepatitis in 16/422 isoniazid versus 3/418 rifampin recipients. Conversely, in 232,889 propensity-matched statin initiators in each baseline ALT stratum, severe acute liver injury was uncommon, with a pooled hazard ratio of 1.15 (95% confidence interval 0.75-1.75) comparing elevated versus normal baseline ALT. CYP3A functional studies found oral midazolam exposure only 5.7% of control values in patients taking carbamazepine or phenytoin, but 12.4-fold greater after 14 days of ritonavir-boosted saquinavir.
Conclusion
Hepatic biochemical abnormalities neither universally indicate hepatocellular dysfunction nor predict a uniform change in drug clearance. Extended treatment can cause hepatotoxicity, produce adaptive enzyme induction or inhibition, or, less commonly, lead to structural hepatic disease. Drug-specific longitudinal monitoring and pharmacokinetic assessment are complementary.
Zitieren
APA
Satapathy, S., Singh, S., & Singh, R. R. (2026). From Hepatic Enzyme Alterations to Drug Metabolic Dysfunction: A Systematic Review of Prolonged Pharmacotherapy. Journal of Diabetes, Metabolism and Endocrinology. https://doi.org/10.61336/jdme.0704.10
Vancouver
Satapathy S, Singh S, Singh RR. From Hepatic Enzyme Alterations to Drug Metabolic Dysfunction: A Systematic Review of Prolonged Pharmacotherapy. Journal of Diabetes, Metabolism and Endocrinology. 2026. doi:10.61336/jdme.0704.10
BibTeX
@article{Satapathy2026,
author = {Satapathy, Sarthak and Singh, Shalu and Singh, Ravi Ranjan},
title = {From Hepatic Enzyme Alterations to Drug Metabolic Dysfunction: A Systematic Review of Prolonged Pharmacotherapy},
journal = {Journal of Diabetes, Metabolism and Endocrinology},
year = {2026},
doi = {10.61336/jdme.0704.10}
}
EUVIMED